Are Biotech ETFs In Trouble As Coronavirus Dims Guidance?

Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.